17 citations
,
June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology” FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
June 2015 in “Reactions Weekly” A man developed alopecia areata after starting cancer treatment with vandetanib.
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
3 citations
,
January 2018 in “Journal of South Asian Federation of Obstetrics and Gynaecology” Letrozole is better for single follicle development and endometrial thickness in PCOS, with no significant difference in pregnancy rates compared to clomiphene.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
1 citations
,
January 2024 in “The Journal of Dermatology” Taxane-based chemotherapy causes more hair loss and skin changes in Asian breast cancer patients.
November 1999 in “Reactions Weekly” 1 citations
,
May 2017 in “Journal of Clinical Oncology” Topical calcitriol is safe for preventing hair loss during chemotherapy.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
August 2006 in “JNCI Journal of the National Cancer Institute” 14 citations
,
June 1995 in “The Journal of Clinical Endocrinology and Metabolism” March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
July 2025 in “International Journal of Pharmacy and Pharmaceutical Science” Herbal medicine may help treat breast cancer and improve quality of life.
May 2025 in “Journal of the ASEAN Federation of Endocrine Societies” Thorough evaluation is crucial for postmenopausal women with virilization to detect rare ovarian tumors.
Nanostructured lipid carriers can improve androgenic alopecia treatment by reducing dutasteride dosage and maintaining its presence in hair follicles longer.
March 2025 in “Drug Development Research” The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.
7 citations
,
May 2022 in “Indonesian Journal of Science and Technology” Compounds from Etlingera alba may help treat Triple Negative Breast Cancer.
June 2018 in “The Journal of Sexual Medicine” Finasteride helps female-pattern hair loss.
Tadalafil may reduce the risk of major heart events and blood clots in men with urinary symptoms.
35 citations
,
July 2022 in “Frontiers in Integrative Neuroscience” Formononetin may help protect the brain and treat neurological diseases.
January 2020 in “Indian Journal of Pharmaceutical Sciences” Kuntai capsules combined with nilestriol tablets effectively reduce perimenopausal symptoms and improve hormone levels.
April 2018 in “Journal of Investigative Dermatology” Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
August 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
January 1994 in “JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS” Testosterone and fleece-flower root affect mouse hair growth.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
October 2023 in “Journal of the Endocrine Society” A woman's ovarian fibroma caused high testosterone levels, which normalized after surgery.
April 2026 in “Preprints.org” Cold Atmospheric Plasma shows promise in treating aggressive breast cancer by targeting cancer cells while sparing normal tissue.